Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination

Tyros, Georgios; Mastraftsi, Styliani; Gregoriou, Stamatis; Nicolaidou, Electra

doi:10.1177/0956462420958577

Cited by 26 publications

(23 citation statements)

References 60 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all the of anogenital warts (90%) are caused by low-risk HPVs which do not have oncogenic potential, even if occasional highrisk types are detected as co-infections with HPV 6 and 11 [51]. Despite most anogenital warts are considered benign lesions, in some cases they are associated with an increased risk of developing grade 2 or worse cervical intraepithelial neoplasia (CIN), intraepithelial neoplasia, and anogenital cancer [52].…”

Section: Benignmentioning

confidence: 99%

Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?

Milano¹,

Guarducci²,

Nante³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background and aim: Human Papillomavirus (HPV) is sexually transmitted, one of the three most common sexually transmitted infections (STIs) in both males and females, and the most common viral STI. A crucial public health strategy to protect people against HPV is through vaccination, which has shown its effectiveness in preventing HPV related diseases. Presently three types of vaccines are available (bivalent, quadrivalent, and nonavalent) and they all target at least the two most oncogenic virus genotypes (HPV 16, 18). In the past few years, the need to implement vaccination programmes that include all genders has been discussed in order to achieve herd immunity against HPV. To date, only a few countries have included young males in their vaccination programmes, so we aim through this review to provide an overview of the epidemiology of HPV and prevention strategies to prevent it, reporting the latest findings from the scientific literature.

show abstract

Section: Benignmentioning

confidence: 99%

Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?

Milano¹,

Guarducci²,

Nante³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…This could be expected due to pre-onset studies on vaccination efficacy [ 89 ]. Hence, HPV vaccination has led to a dramatic decline in anogenital warts and other disease incidences in populations that have achieved high vaccination rates [ 86 , 90 ]. Similar, with the increasing utilization of the 9-valent and quadrivalent HPV vaccine in Australia, Benedict and Derkay [ 91 ] have seen a significant decrease in the incidence of recurrent respiratory papillomatosis.…”

Section: Vaccinationmentioning

confidence: 99%

Relevance of Human Papillomaviruses in Head and Neck Cancer—What Remains in 2021 from a Clinician’s Point of View?

Hoffmann

Quabius

2021

Viruses

View full text Add to dashboard Cite

Human papillomaviruses (HPV) cause a subset of head and neck cancers (HNSCC). HPV16 predominantly signs responsible for approximately 10% of all HNSCC and over 50% of tonsillar [T]SCCs. Prevalence rates depend on several factors, such as the geographical region where patients live, possibly due to different social and sexual habits. Smoking plays an important role, with non-smoking patients being mostly HPV-positive and smokers being mostly HPV-negative. This is of unparalleled clinical relevance, as the outcome of (non-smoking) HPV-positive patients is significantly better, albeit with standard and not with de-escalated therapies. The results of the first prospective de-escalation studies have dampened hopes that similar superior survival can be achieved with de-escalated therapy. In this context, it is important to note that the inclusion of p16INK4A (a surrogate marker for HPV-positivity) in the 8th TMN-classification has only prognostic, not therapeutic, intent. To avoid misclassification, highest precision in determining HPV-status is of utmost importance. Whenever possible, PCR-based methods, still referred to as the "gold standard”, should be used. New diagnostic antibodies represent some hope, e.g., to detect primaries and recurrences early. Prophylactic HPV vaccination should lead to a decline in HPV-driven HNSCC as well. This review discusses the above aspects in detail.

show abstract

“…Current existing treatment modalities aim to destruct and remove all visible lesions mechanically 6 or induce an immune cytotoxic response against infected cells 7 . Regardless of the therapeutic modality, recalcitrance and recurrence rates are high and associated with personal discomfort and psychological distress as well as a significant financial burden to health care systems 8,9 …”

Section: Introductionmentioning

confidence: 99%

“…7 Regardless of the therapeutic modality, recalcitrance and recurrence rates are high and associated with personal discomfort and psychological distress as well as a significant financial burden to health care systems. 8,9 Three HPV vaccines targeting high-risk HPV types are currently available and include 2-, 4-, and 9-valent vaccines. The vaccines are given prophylactically with the aim to prevent transformation of lesions into cervical, vaginal, and anal carcinomas, while the 4-and 9-valent vaccines also aim to prevent genital warts.…”

mentioning

confidence: 99%

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Bar‐Ilan,

Bar,

Baniel

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9‐valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9‐valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9‐valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.

show abstract

Incidence of anogenital warts: epidemiological risk factors and real-life impact of human papillomavirus vaccination

Cited by 26 publications

References 60 publications

Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?

Human Papillomavirus Epidemiology and Prevention: Is There Still a Gender Gap?

Relevance of Human Papillomaviruses in Head and Neck Cancer—What Remains in 2021 from a Clinician’s Point of View?

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Contact Info

Product

Resources

About